Princeton Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Princeton Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$711K	Sell	1,140 -79	-6%	-$53.8K	0.16%	58
2026 Q1	$942K	Sell	1,219 -21	-2%	-$16.1K	0.26%	52
2025 Q4	$957K	Buy	1,240 +25	+2%	+$17K	0.25%	50
2025 Q3	$683K	Sell	1,215 -25	-2%	-$14.1K	0.18%	56
2025 Q2	$651K	Buy	1,240 +23	+2%	+$12.8K	0.19%	56
2025 Q1	$772K	Sell	1,217 -18	-1%	-$12.4K	0.27%	50
2024 Q4	$880K	Sell	1,235 -10	-0.8%	-$8.39K	0.27%	46
2024 Q3	$1.31M	Sell	1,245 -39	-3%	-$43.4K	0.41%	41
2024 Q2	$1.35M	Buy	1,284 +392	+44%	+$380K	0.44%	41
2024 Q1	$859K	Buy	892 +35	+4%	+$33.3K	0.31%	53
2023 Q4	$753K	Buy	857 +14	+2%	+$11.5K	0.3%	55
2023 Q3	$694K	Hold	843	–	–	0.32%	56
2023 Q2	$606K	Buy	843 +85	+11%	+$65.5K	0.25%	56
2023 Q1	$623K	Sell	758 -16	-2%	-$12.1K	0.27%	60
2022 Q4	$558K	Hold	774	–	–	0.25%	67
2022 Q3	$533K	Buy	774 +16	+2%	+$10.1K	0.23%	64
2022 Q2	$448K	Hold	758	–	–	0.17%	71
2022 Q1	$529K	Sell	758 -16	-2%	-$10.1K	0.16%	71
2021 Q4	$489K	Buy	774 +89	+13%	+$54.7K	0.14%	76
2021 Q3	$415K	Hold	685	–	–	0.13%	79
2021 Q2	$383K	Buy	685 +13	+2%	+$6.59K	0.12%	79
2021 Q1	$318K	Buy	+672	New	+$327K	0.11%	84
2019 Q4	–	Sell	-265	Closed	-$74K	–	184
2019 Q3	$74K	Hold	265	–	–	0.04%	128
2019 Q2	$83K	Hold	265	–	–	0.04%	125
2019 Q1	$109K	Sell	265 -11	-4%	-$4.53K	0.06%	114
2018 Q4	$103K	Sell	276 -197	-42%	-$72.1K	0.06%	116
2018 Q3	$191K	Sell	473 -2,804	-86%	-$1.07M	0.08%	100
2018 Q2	$1.13M	Sell	3,277 -49	-1%	-$15.3K	0.49%	39
2018 Q1	$1.15M	Sell	3,326 -358	-10%	-$125K	0.51%	40
2017 Q4	$1.39M	Buy	+3,684	New	+$1.49M	0.62%	36

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Princeton Capital Management's REGN Position: Q2 2026 in Review

Princeton Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 6.5% in Q2 2026, selling an estimated $53.8K and leaving 1,140 shares worth $711K. The position accounts for 0.16% of the portfolio, ranked #58.

Princeton Capital Management first reported a position in REGN in Q4 2017 and has held it in 30 quarters since. The position peaked at $1.39M in Q4 2017. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Princeton Capital Management held 1,140 shares of Regeneron Pharmaceuticals worth $711K as of Q2 2026.
Princeton Capital Management sold 79 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $53.8K.
Regeneron Pharmaceuticals made up 0.16% of Princeton Capital Management's portfolio in Q2 2026, its #58 holding.
Princeton Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 30 quarters since.
Princeton Capital Management's Regeneron Pharmaceuticals position peaked at $1.39M in Q4 2017.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Princeton Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.